← All trials
NCT04815993
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 22, 2021
- Primary completion
- May 18, 2021
- Completion date
- Sep 30, 2021
- First posted
- Mar 25, 2021
- Last posted
- Oct 15, 2021
- Enrollment
- 24
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Synthetic BiologicsLead sponsor
- Spaulding Clinical Research Inc.Overall official - principal investigator
- Spaulding Clinical Research Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.